# CORONA Remedies Limited (CORONA)

> CORONA closed at ₹2,149.60 on 30 Oct 2026, trailing P/E 63.5, market cap ₹13,147 cr, latest results for the quarter ended 30 Sept 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

CORONA Remedies Limited (NSE: CORONA) closed at ₹2,149.60 on 30 Oct 2026, against a 52-week range of ₹1,336.60 – ₹2,292.40.

In the quarter ended 30 Sept 2026 (consolidated, filed 30 Oct 2026) it reported revenue of ₹441 cr and net profit of ₹60 cr, a 13.7% net margin; revenue grew 22.2% and profit grew 15.8% year on year.

On four consecutive filed quarters its trailing P/E is 63.5.

From the balance sheet dated 30 Sept 2026: return on equity 30.0%, ROCE 36.5%, debt-to-equity 0.12, Piotroski F-score 3 of 9.

Against 66 Healthcare peers on NSE: Net margin higher than 55% of 64 sector peers; PBT margin higher than 53% of 64 sector peers; ROE higher than 95% of 64 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹2,149.60 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | +1.8% / +31.6% / — |
| 52-week low – high | ₹1,336.60 – ₹2,292.40 |
| Market capitalisation | ₹13,147 cr |
| Trailing P/E | 63.5 |
| Price / book | 16.33 |
| EV / EBITDA | 40.4 |
| Earnings yield | 1.6% |
| TTM EPS | ₹33.85 |
| TTM net profit | ₹207 cr |
| Quarter revenue | ₹441 cr |
| Quarter net profit | ₹60 cr |
| Net margin | 13.7% |
| Revenue growth (YoY) | +22.2% |
| Profit growth (YoY) | +15.8% |
| Return on equity | 30.0% |
| ROCE | 36.5% |
| Debt / equity | 0.12 |
| Current ratio | 1.42 |
| Free cash flow | ₹86 cr |
| Piotroski F-score | 3 / 9 |
| Average daily turnover (50 days) | ₹3.4 cr |

## Questions

### What is the P/E ratio of CORONA Remedies Limited?

CORONA Remedies Limited's trailing P/E is 63.5, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026.

### What were CORONA Remedies Limited's latest quarterly results?

For the quarter ended 30 Sept 2026, CORONA Remedies Limited reported revenue of ₹441 cr and net profit of ₹60 cr (consolidated), filed with the exchange on 30 Oct 2026.

### What is CORONA Remedies Limited's ROE?

Return on equity is 30.0% based on the balance sheet dated 30 Sept 2026.

### Does CORONA Remedies Limited have debt?

Debt-to-equity is 0.12 on the balance sheet dated 30 Sept 2026.

### What is CORONA's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, CORONA traded between ₹1,336.60 and ₹2,292.40.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/CORONA

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._